Sunshine Biopharma Incorporated (SBFM)

Over the past six months, Sunshine Biopharma reported its fiscal 2025 revenue with a slight increase, launched new generic drugs, and announced planned cost reductions. The company also reported its Q4 2025 earnings. Health Canada authorized the commercialization of Domperidone through Nora Pharma. The company launched Doxycycline in Canada. Sunshine Biopharma launched Pravastatin, leading to a stock price surge. The company highlighted its multi-axis execution and reported Q1 and Q2 revenue increases. The stock has experienced a decline since January 1, 2026, and over the past year.

There is no explicit data indicating significant demand seasonality for Sunshine Biopharma, Inc.'s products and services. Observed stock performance patterns are not necessarily indicative of seasonal demand for the company's pharmaceutical products or nutritional supplements.

Sunshine Biopharma, Inc. (SBFM) is a pharmaceutical and biotechnology company focused on researching, developing, and commercializing oncology and antiviral drugs, as well as science-based nutritional supplements. The company operates in the Health Technology sector, specifically in the Pharmaceuticals: Major industry, and is classified under pharmaceutical preparations. Sunshine Biopharma integrates a commercial generics and biosimilars platform with an internal proprietary drug development program. Through its subsidiary, Nora Pharma Inc., it markets over 70 generic prescription drugs in Canada across various therapeutic areas and has entered the biosimilars market with NIOPEG. The company is also advancing drug candidates like K1.1 mRNA for liver cancer, PLpro protease inhibitor (SBFM-PL4) for SARS coronavirus infections, and Adva-27a for pancreatic and other cancers. Its OTC products include Essential 9 amino acid supplement, Essential Calcium-Vitamin D supplement, L-Citrulline, and Taurine products.

Sunshine Biopharma, Inc. is headquartered in Fort Lauderdale, Florida, USA, and has operations in Montreal, Canada. The company's pharmaceutical products are offered and researched in the United States and Canada. Its generic prescription drugs are primarily marketed in Canada through its subsidiary Nora Pharma Inc.

Sunshine Biopharma's reputation has been influenced by its commercial activities and drug development progress. The company has expanded its portfolio of generic drugs in Canada, with new launches and regulatory approval. These commercial successes and revenue growth contribute positively to its market presence. However, the Adva-27a program for pancreatic cancer faced a delay due to unfavorable lab results, leading to the termination of a research agreement, which could impact its reputation in the innovative drug development space. The K1.1 mRNA and PLpro inhibitor programs remain on track for potential Phase 1 clinical trials.

Sunshine Biopharma, Inc. is owned by a mix of institutional, insider, and retail investors. Malek Chamoun is the largest individual shareholder. Insider ownership accounts for a significant portion of the company, while retail investors hold a smaller percentage. Institutional ownership varies. Major institutional owners and shareholders include Citadel Advisors Llc, Virtu Financial LLC, XTX Topco Ltd, Morgan Stanley, SBI Securities Co., Ltd., UBS Group AG, Advisor Group Holdings, Inc., National Bank Of Canada /fi/, Bank Of America Corp /de/, Strive Financial Group, LLC, Altium Capital Management LLC, Connective Capital Management LLC, Two Sigma Investments LP, L1 Capital Global, Inc., Citadel Securities GP LLC and Osaic Wealth, Inc.